Loading
companiesCompany
Zai Lab
Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets.
Also called: 再鼎医药
Overview
Founded by Samantha Du; built on Greater China rights to niraparib (Zejula), zanidatamab, repotrectinib, tislelizumab-adjacent assets, sulbactam-durlobactam and Optune, with a Shanghai commercial organisation of hundreds. Internal pipeline: ZL-1310 (DLL3 ADC), ZL-1503 and the LRRC15 ADC ZL-6201 from MediLink. A bridge company: it explains how Western drugs reach Chinese patients years earlier than they otherwise would.
Headquarters
Shanghai / Cambridge, MA, CN
Scorecard
All companies#32of 1244 companies, score 91
- approved products +24
- phase 3 +3
- targets +10
- modalities +8
- regions +6
- 24-month regulatory events +10
- registry trials +30
4 approved, 1 in phase 3, 0 earlier, 5 targets, 224 registry studies. Formula on the scorecards page.
Type
Biotech · ZLAB / 9688.HK
Stage
Public
Website
Founded
2014
ApprovedSmall-molecule PARP inhibitor
Niraparib · Zejula
Niraparib is a PARP inhibitor approved as maintenance for ovarian cancer regardless of BRCA status, and in prostate cancer with abiraterone.
ApprovedBiparatopic bispecific antibody (HER2)
Zanidatamab · Ziihera
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.
ApprovedSmall-molecule kinase inhibitor (ROS1 / NTRK)
Repotrectinib · Augtyro
A ROS1 and NTRK pill that also works after other ROS1 drugs fail, with dizziness as its signature side effect.
ApprovedDevice (tumour treating fields)
Optune / Optune Pax (TTFields) · Optune
Optune is a wearable device delivering electric fields that disrupt cell division. It is approved for glioblastoma and, in 2026, pancreatic cancer.
Phase 3ADC
ZL-1310 is an experimental antibody-drug conjugate from Zai Lab (Shanghai) in phase 3 trials for non-small-cell lung cancer, aimed at DLL3.
Similar pages
- CompanyHutchmed
Shares Samantha Du (Du Ying) and the tag china.
- CompanyHansoh Pharmaceutical
Shares GSK and the tag china.
- TrialHERIZON-BTC-302
Shares Zymeworks, Jazz Pharmaceuticals, Zanidatamab.
- Key paperZanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Shares Zymeworks, Jazz Pharmaceuticals, Zanidatamab.
- TrialHERIZON-BTC-01
Shares Zymeworks, Jazz Pharmaceuticals, Zanidatamab.
- TreatmentZanidatamab zovodotin
Shares Zymeworks, Zanidatamab.
- TrialSTELLAR
Shares Novocure, Optune / Optune Pax (TTFields).
- TrialEF-14
Shares Novocure, Optune / Optune Pax (TTFields).
fronts
drugs
ApprovedSmall-molecule PARP inhibitor
Niraparib · Zejula
ApprovedDevice (tumour treating fields)
Optune / Optune Pax (TTFields) · Optune
ApprovedSmall-molecule kinase inhibitor (ROS1 / NTRK)
Repotrectinib · Augtyro
ApprovedBiparatopic bispecific antibody (HER2)
Zanidatamab · Ziihera
Phase 3ADC
companies
trials
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line TherA Study of ZL-1310 in Participants With Selected Solid TumorsA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)